Alliance Global Partners lowered the firm’s price target on Aquestive Therapeutics to $5.50 from $7 and keeps a Buy rating on the shares, citing revised share count estimates and a slightly delayed Anaphylm launch compared to the firm’s previous estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Presents to Investors and Analysts
- Aquestive Therapeutics sees FY24 revenue $48M-$51M, consensus $50.21M
- Aquestive Therapeutics reports Q1 EPS (17c), consensus (8c)
- Aquestive Therapeutics Shares Investor Presentation Update
- Aquestive Therapeutics options imply 12.3% move in share price post-earnings